These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19795915)

  • 1. The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.
    Moosavi-Movahedi AA; Mousavy SJ; Divsalar A; Babaahmadi A; Karimian K; Shafiee A; Kamarie M; Poursasan N; Farzami B; Riazi GH; Hakimelahi GH; Tsai FY; Ahmad F; Amani M; Saboury AA
    J Biomol Struct Dyn; 2009 Dec; 27(3):319-39. PubMed ID: 19795915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of deferasirox on the structure and function of bovine liver catalase: a spectroscopic and theoretical study.
    Moradi M; Divsalar A; Saboury AA; Ghalandari B; Harifi AR
    J Biomol Struct Dyn; 2015; 33(10):2255-66. PubMed ID: 25586906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chelation of cadmium by combining deferasirox and deferiprone in rats.
    Jamilaldin Fatemi S; Saljooghi AS; Balooch FD; Iranmanesh M; Golbafan MR
    Toxicol Ind Health; 2011 May; 27(4):371-7. PubMed ID: 21245204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode.
    Hajjizadeh M; Jabbari A; Heli H; Moosavi-Movahedi AA; Shafiee A; Karimian K
    Anal Biochem; 2008 Feb; 373(2):337-48. PubMed ID: 18023399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.
    Chakraborty D; Bhattacharyya M
    Mol Cell Biochem; 2000 Jan; 204(1-2):17-20. PubMed ID: 10718620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chelation of aluminum by combining deferasirox and deferiprone in rats.
    Saljooghi AS
    Toxicol Ind Health; 2012 Sep; 28(8):740-5. PubMed ID: 22025507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of interaction between terbium(III)-deferasirox and double helix DNA by spectral and electrochemical methods.
    Shaghaghi M; Dehghan G; Jouyban A; Sistani P; Arvin M
    Spectrochim Acta A Mol Biomol Spectrosc; 2014; 120():467-72. PubMed ID: 24211806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
    Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J
    Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.